Patrícia Silva, PhD,  director of science content—

GlaxoSmithKline (GSK) recently announced that the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has released a positive recommendation for its application to expand the existing therapeutic indication for pulmonary arterial hypertension (PAH) combination treatment Volibris® (ambrisentan) — a selective endothelin type-A receptor antagonist. The therapy is currently approved…

Patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH) or recurrent CTEPH in Wales now have access to Bayer’s therapy Adempas (riociguat) — a soluble guanylate cyclase (sGC) stimulator that works by relaxing blood vessels and increasing the supply of blood to the lungs, which helps reduce the workload of the heart. The All Wales Medicines…

North Bergen, New Jersey locals Carlos Torres and Martha Gonzalez reported in a recent press release that they felt “extremely blessed” upon witnessing Pope Francis kiss their 9-year-old son, Daniel, during His Holiness’ New York City visit, believing that the Pope’s blessing may help Daniel fight…

Actelion Pharmaceuticals, a biopharmaceutical company developing pulmonary arterial hypertension (PAH) therapies, recently announced the presentation of further data from its pivotal Phase III GRIPHON study testing investigational PAH treatment selexipag (Uptravi) during the 2015 European Respiratory Society (ERS) Congress, which will take place in Amsterdam, Netherlands. The presentation is titled…

Brooklyn Brazilian Jiu-Jitsu, the city’s leading consortium of martial arts schools across Bensonhurst, Cobble Hill, Clinton Hill, Dyker Heights and Gravesend, is showing its commitment to supporting charities by pledging funds raised all throughout last month to the Pulmonary Hypertension Association to help fund patient services and urgent research programs geared…

The Pulmonary Hypertension Association (PHA) is currently hosting the 2015 PH Professional Network (PHPN) Symposium, which began on Thursday, September 17 and will run until Saturday, September 19 at the Crystal Gateway Marriott in Arlington, Va. Invited to give an inspiring and insightful talk on her story as a PH patient is Pam Kehoe,…

Sunshine Heart, Inc., an early-stage medical device company focused on developing, manufacturing and commercializing the C-Pulse System for treatment of Class III and ambulatory Class IV heart failure, has announced the start of a research collaboration with Dr. Mark Slaughter and the University of Louisville to explore the technology’s potential benefits for…

The European Society of Cardiology (ESC) together with the European Respiratory Society (ERS) recently launched a new treatment algorithm for pulmonary arterial hypertension in its updated pulmonary hypertension guidelines. The amended protocol aims to provide patients with the best chance of a positive clinical outcome despite being diagnosed with…

Gilead Sciences, Inc. recently announced the publication of data in The New England Journal of Medicine concerning the AMBITION trial evaluating the combination therapy of Letairis® (ambrisentan) and tadalafil for pulmonary arterial hypertension (PAH). The AMBITION trial (NCT01178073) is a multicenter, randomized, double-blind…

Actelion Pharmaceuticals Ltd recently announced in a press release that new data on its investigational drug selexipag (Uptravi®) and the approved macitentan (Opsumit®) for pulmonary arterial hypertension will be presented at the upcoming European Society of Cardiology (ESC) Congress in London, United Kingdom, August 29 to September…

Results from a recent study published in the journal Circulation: Cardiovascular Imaging showed that pediatric patients with Pulmonary hypertension have reduced Left Ventricular  strain/strain rate, predominantly within the septum, with relationships to invasive hemodynamics, right ventricular strain, and functional Pulmonary hypertension measures. Pulmonary hypertension (PH) is raised…

A new study recently published in the Chinese Medical Journal revealed that a 6-month warfarin treatment might not be sufficient as an effective therapy for patients with pulmonary embolism complicated by obstructive sleep apnea hypopnea syndrome (OSAHS). The study was conducted by researchers at Beijing Anzhen Hospital…